论文部分内容阅读
目的:观察瑞格列奈治疗糖尿病的临床效果。方法:2型糖尿病患者130例根据治疗组药物的不同分为治疗组与对照组各65例,治疗组给予瑞格列奈治疗,对照组给予格列齐特缓释片治疗。结果:治疗组的血糖达标率为76.9%,对照组为46.2%,2组对比差异明显(P<0.05)。治疗组治疗后生活质量中的社会、心理、环境与生理指标得分明显低于对照组(P<0.05)。结论:瑞格列奈治疗糖尿病能有效控制血糖,提高患者预后生活质量,但是也要加强多种干预方法的综合使用。
Objective: To observe the clinical effect of repaglinide in the treatment of diabetes. Methods: One hundred and thirty-three patients with type 2 diabetes were divided into treatment group and control group with 65 cases in each group. The treatment group was treated with repaglinide, while the control group was treated with gliclazide sustained-release tablets. Results: The blood glucose compliance rate was 76.9% in the treatment group and 46.2% in the control group, with significant difference between the two groups (P <0.05). The scores of social, psychological, environmental and physical indicators of the quality of life after treatment in the treatment group were significantly lower than those in the control group (P <0.05). Conclusion: The treatment of diabetes with repaglinide can effectively control blood sugar and improve the quality of life of patients with prognosis. However, it is necessary to strengthen the comprehensive use of multiple interventions.